PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34601503-0	2021	Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase.	Metformin	0-9	dihydrofolate reductase	Homo sapiens	72-95	
34601503-3	2021	Herein, we report that metformin treatment increases the sensitivity of hepatocarcinoma cells to methotrexate (MTX) by suppressing the expression of the one-carbon metabolism enzyme DHFR.	Metformin	23-32	dihydrofolate reductase	Homo sapiens	182-186	
34601503-5	2021	Mechanistically, metformin not only transcriptionally represses DHFR via E2F4 but also promotes lysosomal degradation of the DHFR protein.	Metformin	17-26	dihydrofolate reductase	Homo sapiens	64-68	
34601503-5	2021	Mechanistically, metformin not only transcriptionally represses DHFR via E2F4 but also promotes lysosomal degradation of the DHFR protein.	Metformin	17-26	dihydrofolate reductase	Homo sapiens	125-129	
34601503-7	2021	Taken together, our findings identify an important role for DHFR in the suppressive effects of metformin on therapeutic resistance, thus revealing a therapeutically targetable potential vulnerability in hepatocarcinoma.	Metformin	95-104	dihydrofolate reductase	Homo sapiens	60-64